ORIC Pharmaceuticals Q3 net loss narrows to $32.6 mln

ORIC Pharmaceuticals

13/11/2025 21:30

Overview

ORIC Pharmaceuticals reports Q3 net loss of $32.6 mln, with decreased operating expenses

Cash and investments of $413 mln expected to fund operations into 2H 2028

Outlook

Company anticipates cash to fund operations into 2H 2028

Result Drivers

LEADERSHIP APPOINTMENT - Appointment of Kevin Brodbeck, PhD, as Chief Technical Officer to support late-stage development

Research and development (R&D) expenses were $28.8 million for the three months ended September 30, 2025

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Net Income
-$32.59 mln
Q3 Income from Operations
-$36.67 mln
Q3 Operating Expenses
$36.67 mln


Analyst Coverage

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 12 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy."

Wall Street's median 12-month price target for Oric Pharmaceuticals Inc is $19.50, about 36% above its November 12 closing price of $12.48

Press Release: ID:nGNX8ZDPmY

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)